title: Cisapride does not improve precolonoscopy bowel preparation with either sodium phosphate or polyethylene glycol electrolyte lavage.
abstract: BACKGROUND
  Oral sodium phosphate solution (NAP) and polyethylene glycol-electrolyte lavage (PEG-EL) are used for precolonoscopy bowel preparation. The benefit of adding cisapride to PEG-EL is controversial, and its influence on the effectiveness of NAP has not been investigated. The primary aim of this study was to determine whether cisapride improves the effectiveness and/or tolerableness of bowel preparation with either NAP or PEG-EL.
  
  
  METHODS
  In 187 patients undergoing colonoscopy, a randomized, double-blind, placebo-controlled trial with a Latin square design was conducted to compare 4 different bowel preparations: NAP plus either cisapride (10 mg; 2 doses) or placebo, or PEG-EL plus either cisapride (10 mg; 1 dose) or placebo. Quality of the bowel preparation was graded by the endoscopist according to the amount of stool present in the colon (excellent, satisfactory, unsatisfactory). To assess tolerability, patients rated 8 symptoms, the taste of the lavage solution, and the ease of preparation on a 5-point scale (1: easy; 5: distressing).
  
  
  RESULTS
  Endoscopists scored the bowel preparation as either excellent or satisfactory as follows: NAP: cisapride 50% versus placebo 61% (p = 0.3); PEG-EL: cisapride 80% versus placebo 78% (p = 1.0). Cisapride did not improve tolerability or the frequency of adverse symptoms associated with either solution. The ease of bowel preparation was significantly better in the NAP group versus PEG-EL group (mean score 1.8 versus 2.8; p < 0.0001).
  
  
  CONCLUSIONS
  Cisapride does not improve the quality of bowel preparation with either NAP or PEG-EL. NAP is better tolerated by patients than PEG-EL; however, PEG-EL results in better bowel preparation.
authors.affiliation: Division of Gastroenterology, CHUV, Lausanne, Switzerland, and ClinResearch, Cologne, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Martínek
authors.forename: J
authors.initials: J
authors.lastname: Hess
authors.forename: J
authors.initials: J
authors.lastname: Delarive
authors.forename: P
authors.initials: P
authors.lastname: Jornod
authors.forename: A
authors.initials: A
authors.lastname: Blum
authors.forename: D
authors.initials: D
authors.lastname: Pantoflickova
authors.forename: M
authors.initials: M
authors.lastname: Fischer
authors.forename: G
authors.initials: G
authors.lastname: Dorta
mesh_terms: D000284:Administration, Oral; D020117:Cisapride / Q000008:administration & dosage*; D003113:Colonoscopy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010342:Patient Acceptance of Health Care; D010710:Phosphates / Q000008:administration & dosage* / Q000009:adverse effects; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000009:adverse effects; D012996:Solutions; D007507:Therapeutic Irrigation / Q000379:methods*
chemical_list: D010710:Phosphates; D012996:Solutions; D011092:Polyethylene Glycols; C018279:sodium phosphate; D020117:Cisapride